Photo from wikipedia
CGRP monoclonal antibody (mAb) is a promising preventive treatment for episodic migraine and has been approved by US FDA recently. But the treatments for chronic migraine are rare. Therefore, we… Click to show full abstract
CGRP monoclonal antibody (mAb) is a promising preventive treatment for episodic migraine and has been approved by US FDA recently. But the treatments for chronic migraine are rare. Therefore, we performed meta‐analysis to assess the efficacy and safety of CGRP mAbs in preventing chronic migraine.
Keywords:
migraine;
meta analysis;
chronic migraine;
preventive treatment;
cgrp monoclonal;
monoclonal antibody
Journal Title: Brain and Behavior
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Brain and Behavior
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!